Details for Patent: 12,390,474

Which drugs does patent 12,390,474 protect, and when does it expire?

Patent 12,390,474 protects LYBALVI and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 12,390,474

Title:	Immediate release multilayer tablet
Abstract:	Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Inventor(s):	Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Assignee:	Alkermes Pharma Ireland Ltd
Application Number:	US18/510,585
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,390,474
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 12,390,474

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021		RX	Yes	Yes	12,390,474		Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021		RX	Yes	No	12,390,474		Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	12,390,474		Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	12,390,474		Y

International Family Members for US Patent 12,390,474

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	4243768
World Intellectual Property Organization (WIPO)	2022101444